Ductal Carcinoma In Situ (DCIS) is a type of non-invasive breast cancer, meaning it is confined to the milk ducts and has not spread to surrounding breast tissue. DCIS is considered the earliest form of breast cancer and is often referred to as a "precancerous" condition. In DCIS, abnormal cells are present inside the milk ducts, but they have not yet invaded the surrounding tissue or spread to other parts of the body. It is typically detected through routine mammograms, often before any physical signs or symptoms are noticeable. While it is not life-threatening at this stage, DCIS can develop into invasive cancer if left untreated, which is why it is important to monitor and treat it.

​

Treatment for DCIS usually involves a combination of surgery and sometimes radiation therapy. The primary treatment is a lumpectomy, where the abnormal tissue is removed, and sometimes the surrounding healthy tissue to ensure clear margins. In some cases, a mastectomy (removal of the entire breast) may be recommended, especially if the DCIS is widespread or if the patient has other risk factors. Radiation therapy may also be used after a lumpectomy to reduce the risk of the DCIS recurring in the breast. Hormone therapy might be offered if the DCIS is hormone receptor-positive, as this can help prevent the development of invasive cancer.

​

Though DCIS is not an immediate threat to life, its diagnosis can be a source of concern due to the potential for progression to invasive breast cancer. However, the prognosis for DCIS is generally very good, especially when detected early and treated promptly. The majority of women with DCIS go on to live long, healthy lives. The treatment approach varies depending on the size, location, and grade of the DCIS, as well as the patient’s preferences and overall health. Ongoing monitoring with follow-up imaging is essential to ensure that no new areas of concern develop.